The Oslo Patient: A Brother's Bone Marrow, a Genetic Lottery, and the Stubborn Math of Curing HIV

A Norwegian man is almost certainly free of HIV, five years after receiving his brother's stem cells. The case is remarkable — and almost entirely unrepeatable.

The Fortunate Coincidence

In 2006, a man in Oslo was diagnosed with HIV at age 44. By 2010, he had started antiretroviral therapy (ART), the daily medication regimen that suppresses HIV replication and prevents progression to AIDS [1]. His viral load dropped to undetectable levels, and for years he lived as millions of other people on ART do — managing a chronic condition with reliable drugs.

Then in 2017, he received a second, more ominous diagnosis: myelodysplastic syndrome, a potentially fatal blood cancer that required a bone marrow transplant [2]. His medical team at Oslo University Hospital searched international registries for a compatible donor who also carried two copies of the CCR5-delta32 mutation — a genetic variant that disables the CCR5 receptor on the surface of immune cells, the primary doorway HIV uses to enter and infect them [3]. They found no match.

So they turned to the patient's brother, a suitable donor for the cancer treatment. On the day of the transplant in 2020, the team made an unexpected discovery: the brother happened to be homozygous for CCR5-delta32, carrying two copies of the mutation that confers near-total resistance to HIV [2]. It was, as virologist Mari Kaarbø of Oslo University Hospital later described it, "a fortunate coincidence" [4].

What the Evidence Shows

Two years after the transplant, the patient stopped taking antiretroviral drugs under medical supervision. The research team — led by Dr. Anders Eivind Myhre, with collaboration from IrsiCaixa in Barcelona and Aarhus University Hospital in Denmark — then subjected his body to rigorous testing [4].

They used droplet digital PCR (ddPCR) to quantify total HIV DNA in his blood and tissue. They deployed the Intact Proviral DNA Assay (IPDA), which specifically measures proviruses — dormant copies of HIV integrated into host cell DNA — that retain the potential to reactivate. And they performed a Quantitative Viral Outgrowth Assay (QVOA) in Aarhus, which activates CD4+ T cells to determine whether any latent virus can still produce infectious particles [4].

The gut was extensively tested, because it is where HIV most commonly persists in its dormant state. Results from all three laboratories found no detectable active virus in blood, gut, or bone marrow samples [1][4]. Study co-author Marius Trøseid of the University of Oslo confirmed that the patient's immune system had been "completely replaced" by the donor's [2].

"For all practical purposes, we are quite certain that he is cured," stated Dr. Myhre [2]. The case was published in Nature Microbiology in April 2026 [5]. Four years after stopping ART, the virus remains undetectable.

Whether this meets the field's standard for "sterilizing cure" — the complete elimination of every HIV-infected cell — versus "functional cure" — long-term remission without medication — remains a point of scientific discussion. The absence of replication-competent virus in outgrowth assays and the inability to detect intact proviral DNA are strong evidence, but HIV researchers generally prefer a minimum of five years off ART before declaring sterilizing cure with confidence [6].

Ten Cases in Two Decades

The Oslo patient is the tenth person to achieve sustained HIV remission following a stem cell transplant. He is also the first to receive donor cells from a biological sibling [5].

Source: amfAR / Nature Microbiology

Data as of Apr 14, 2026CSV

The timeline of cases reveals both progress and persistent limitations:

Timothy Ray Brown (Berlin Patient, 2006): The first person cured of HIV. Received two transplants for acute myeloid leukemia from a CCR5-delta32 homozygous donor, along with total body irradiation — an aggressive conditioning regimen. Remained HIV-free for over 13 years until his death from leukemia relapse in 2020 [7].

Adam Castillejo (London Patient, 2016): Treated with reduced-intensity chemotherapy (no irradiation) prior to a CCR5-delta32 transplant for Hodgkin lymphoma. Stopped ART in 2017 and remains HIV-free [7].

Marc Franke (Düsseldorf Patient, 2013): Received CCR5-delta32 transplant for acute myeloid leukemia. Discontinued ART in 2018, confirmed cured in 2023 [7].

New York Patient (2019): First haplo-cord blood transplant combining CCR5-delta32 cord blood with adult stem cells from a relative. Off ART for 14 months with no detectable virus at reporting [7].

Paul Edmonds (City of Hope Patient, 2019): Oldest transplant recipient at the time to achieve apparent cure. Living with HIV since 1988 [7].

Geneva Patient (2023): Used "wild-type" donor cells — cells without the CCR5-delta32 mutation — and still achieved remission, suggesting graft-versus-host effects may independently suppress HIV reservoirs [8].

Second Berlin Patient (2024): Achieved remission with a donor carrying only a heterozygous (single copy) CCR5-delta32 mutation. Natural killer cells with an unusual genetic profile appeared central to the outcome [7].

French Patient (2024): Received CCR5-delta32 transplant for acute myeloid leukemia in 2020, stopped ART in October 2023, remains HIV-free [7].

Chicago Patient (2025): Initially experienced viral rebound after stopping ART post-transplant, then achieved sustained remission after a second treatment interruption — a unique trajectory [7].

The variations across these cases — different conditioning regimens, different donor mutation profiles, different cancers — are scientifically valuable. The Geneva and Second Berlin cases, where donors lacked homozygous CCR5-delta32, suggest the graft-versus-host immune response itself may help clear HIV reservoirs, independent of the CCR5 mutation [8][7].

The Genetic Bottleneck

The CCR5-delta32 mutation exists almost exclusively in populations of Northern European descent. Allele frequencies range from 16.4% in Norway to roughly 10% across Germany and the UK, dropping to around 2% in the Middle East and below 1% in East Asia. In Sub-Saharan Africa — where the majority of the world's 40.8 million people living with HIV reside — the mutation is virtually absent [9][10].

Source: DKMS / PLOS Biology

Data as of Jan 1, 2017CSV

Homozygous carriers (people with two copies) are far rarer than heterozygous carriers. With a 10% allele frequency, Hardy-Weinberg equilibrium predicts roughly 1% of Northern Europeans are homozygous [9]. Globally, the figure drops well below that.

For a patient to benefit from this approach, they need: (1) a blood cancer or other condition that independently justifies the extreme risk of a stem cell transplant; (2) a biologically compatible donor; and (3) that donor must be homozygous for CCR5-delta32. The probability of a given HIV-positive person having a compatible sibling who also carries two copies of the mutation is vanishingly small. Applied to the 40.8 million people living with HIV worldwide [10], the realistic candidate population for this exact procedure numbers in the low hundreds at most — and that assumes those patients also have a medical need for the transplant itself.

The Risk Calculus

Allogeneic stem cell transplantation is not a benign procedure. It involves destroying a patient's existing bone marrow with chemotherapy or radiation, then replacing it with donor cells. The primary complications include graft-versus-host disease (GVHD), where donor immune cells attack the recipient's body; severe infections due to immune suppression; and organ toxicity from conditioning regimens [11].

Non-relapse mortality — death from the transplant itself rather than the underlying cancer — was 24.4% in the 1990s and has improved to approximately 9.5% in recent years [11]. Among all causes of death following transplant, relapse accounts for 46%, GVHD for 22.1%, and infections for 12.1% [11].

For patients who already need a transplant to treat cancer — as the Oslo patient did — attempting to cure HIV simultaneously is a reasonable secondary objective. But for the roughly 31.6 million people currently on ART who have achieved viral suppression [10], the transplant's mortality risk is difficult to justify ethically. Modern ART reduces viral load to undetectable levels, prevents transmission, and allows a near-normal life expectancy. Subjecting otherwise stable patients to a procedure with a ~10% mortality rate to cure a condition already managed by daily medication would, by most clinical ethics frameworks, cause more harm than it prevents.

The Economics

The cost disparity between transplantation and ongoing ART varies enormously by geography.

Source: Global Fund / NIH / UNAIDS

Data as of Jan 1, 2024CSV

In the United States, branded first-line ART regimens cost upward of $36,000 per year [12]. Over a 40-year treatment course, that amounts to roughly $1.4 million — making a one-time stem cell transplant at $100,000–$300,000 potentially cost-competitive in high-income settings, before accounting for post-transplant care, complications, and lost productivity during recovery.

But 95% of people living with HIV are in low- and middle-income countries [10]. In sub-Saharan Africa, generic first-line ART costs under $100 per year [13]. The Global Fund has negotiated prices for tenofovir/lamivudine/dolutegravir (TLD) down to $45 per person per year [14]. Over 40 years, that totals $1,800–$4,000 — a fraction of what a single transplant costs in a high-income hospital. In these settings, stem cell transplantation is not only impractical (the infrastructure and donor registries do not exist) but economically irrational as a cure strategy.

The Pharmaceutical Incentive Problem

Gilead Sciences' Biktarvy, the most prescribed HIV drug globally, generated approximately $12 billion in worldwide sales in 2023 alone [15]. The global HIV drug market is projected to reach $52.95 billion by 2034 [16]. Lifelong ART is, in commercial terms, one of the most reliable recurring revenue streams in pharmaceutical history.

This creates a structural tension. Public and philanthropic funding for HIV cure research remains limited, with funders described as "averse to risks" and lacking transparency and consistency in their funding mechanisms [17]. The average cost of developing a new drug reached $2.3 billion in 2022 [17]. A one-time cure — whether via transplant, gene therapy, or another mechanism — would eliminate a patient's lifetime drug spending, which is commercially attractive to payers but threatens manufacturers' revenue base.

This does not mean pharmaceutical companies actively suppress cure research. Gilead, for instance, funds significant HIV research through its own programs. But the economic incentives structurally favor incremental therapeutic improvements (longer-acting injectables, new formulations) over curative approaches that would eliminate the customer relationship entirely. The Oslo case was funded through academic medical channels, not pharmaceutical industry investment [4][2].

CRISPR and the Scalable Path

If stem cell transplants from CCR5-delta32 donors cannot scale, the question becomes whether the same biological principle — disabling CCR5 — can be achieved without a matched donor. CRISPR-Cas9 gene editing offers a potential route: editing a patient's own stem cells to introduce CCR5-delta32-like resistance, then reinfusing them.

Source: OpenAlex

Data as of Jan 1, 2026CSV

Research in this area has accelerated. Over 3,150 papers have been published on CRISPR/CCR5/HIV, with publication peaking at 413 papers in 2023 [18]. In early 2025, researchers achieved CCR5 editing in over 90% of human blood stem cells with minimal off-target effects [19]. A meta-analysis found CCR5 editing produced a 74.5% reduction in HIV-1 susceptibility, with biallelic (both copies) editing conferring substantially stronger protection [20].

Excision Biotherapeutics has completed a Phase I/II trial using CRISPR to directly excise HIV DNA from infected cells, with guide RNAs directing Cas9 to cut at two sites within the integrated HIV genome [19]. In animal models, combined CCR5 editing and HIV proviral excision eliminated HIV DNA in 58% of infected subjects [21].

Significant obstacles remain. Delivery of CRISPR machinery to enough stem cells in a living patient is technically challenging. Off-target editing — cutting DNA at unintended locations — poses safety risks, though recent studies report no detectable genomic instability in long-term animal follow-up [19]. Viral tropism switching, where HIV adapts to use the CXCR4 receptor instead of CCR5, could undermine the approach in some patients [19]. And the economics of gene therapy remain uncertain: current gene therapies for other conditions are priced at $1–3 million per treatment, though costs are expected to fall with manufacturing improvements.

Does the Oslo case accelerate or distract from CRISPR investment? Both, arguably. It reinforces that eliminating CCR5 function leads to durable HIV remission, validating the biological target that CRISPR approaches aim to replicate. But the media attention on individual cure cases can create a misleading impression that the transplant approach itself is nearing scalability, when the real scalable path runs through gene editing.

Source: OpenAlex

Data as of Jan 1, 2026CSV

What the Oslo Case Means — and What It Doesn't

The Oslo patient's outcome is scientifically significant for three reasons. First, it is the first sibling-donor cure, demonstrating that family members can serve as donors when registries fail — relevant for the small number of patients who have both HIV and a transplant-requiring cancer. Second, it adds to the evidence base that full CCR5-delta32 chimerism (complete replacement of the recipient's immune system with CCR5-deficient donor cells) leads to durable remission. Third, it provides new data on HIV reservoir clearance in gut tissue, among the hardest compartments to study [4][5].

What it does not mean is that a cure for HIV is near for the vast majority of patients. The procedure requires a cancer diagnosis that independently warrants transplantation, a compatible donor with the right mutation, access to a high-resource medical center, and tolerance of a procedure that kills roughly one in ten recipients. Of the 40.8 million people living with HIV today [10], the number who could realistically benefit from this exact approach is negligible.

The path to a broadly applicable HIV cure runs through gene editing, therapeutic vaccines, or reservoir-targeting strategies — not through bone marrow transplants. Each of the ten transplant cases is a proof of concept, not a proof of scalability. The Oslo patient's brother gave him a rare gift. The challenge for researchers is to engineer that gift into something available to everyone.